Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LB-P6 + LB-P8 is a probiotic combination consisting of two specific strains of *Lactobacillus plantarum*, LB-P6 and LB-P8, developed by the South Korean biotechnology company LactoMason. This combination is primarily investigated for its potential to improve skin health through the gut-skin axis. Clinical studies, such as NCT04885842, have evaluated its efficacy in reducing skin wrinkles, improving elasticity, and increasing skin moisture content following oral administration. The mechanism involves the modulation of the gut microbiota, which in turn influences systemic inflammatory markers and skin physiology. It is typically developed as a functional food ingredient or a nutricosmetic product for anti-aging and skin barrier support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LB-P6 + LB-P8.